Science

Mohamed Gouda: Selinexor in Combination with Immune Checkpoint Inhibition in Uveal Melanoma

Mohamed Alaa Gouda/researchgate.net

Jan 25, 2025, 04:09

Mohamed Gouda: Selinexor in Combination with Immune Checkpoint Inhibition in Uveal Melanoma

Mohamed Gouda, Clinical Fellow at the University of Texas MD Anderson Cancer Center, shared a post on X about a recent paper by him and colleagues published in Journal of Immunotherapy and Precision Oncology:

“Now published in JIPO: Selinexor (KPT-330) in Combination with Immune Checkpoint Inhibition in Uveal Melanoma.

And interview with Dr. Sapna Patel about the study’s highlights.”

“Selinexor (KPT-330) in Combination with Immune Checkpoint Inhibition in Uveal Melanoma: A Phase 1B Trial “

Authors: Mohamed Gouda, Abdulrazzak Zarifa, Yali Yang, Bettzy Stephen, Serdar Gurses, Ashabari Sprenger, Yanyan Tian, Mohamed Derbala, Isabella Glitza Oliva, Funda Meric-Bernstam, Sapna Patel.

Mohamed Gouda: Selinexor in Combination with Immune Checkpoint Inhibition in Uveal Melanoma

More posts featuring Mohamed Gouda.

Abdulrazzak Zarifa Ashabari Sprenger Bettzy Stephen cancer Funda Meric-Bernstam Isabella Glitza Oliva Mohamed Derbala Mohamed Gouda OncoDaily Oncology Sapna Patel selinexor Serdar Gurses Uveal melanoma Yali Yang Yanyan Tian

Agenus announced new data highlighting BOT/BAL across multiple lines of treatment in Colorectal Cancer

President Trump has announced U.S. Withdrawal from the World Health Organization

OncoDaily Acquires CancerWorld: A New Era in Oncology Media

FDA approved sotorasib with panitumumab for KRAS G12C-mutated colorectal cancer

Oncologist Near Me - Vivek Subbiah: Pionner of Precision Oncology